找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Dose Finding and Beyond in Biopharmaceutical Development; Jingjing Ye,Ding-Geng Chen,Joseph C. Cappelleri Book 2025 The Editor(s) (if appl

[复制链接]
楼主: EVOKE
发表于 2025-3-23 13:19:56 | 显示全部楼层
发表于 2025-3-23 17:56:40 | 显示全部楼层
发表于 2025-3-23 18:00:37 | 显示全部楼层
,Wie demokratisch ist die Türkei?,(ed) Dose finding in drug development. Springer, New York, p 146–171, 2006) to confirm the proof of concept and identify the minimum effective dose (MED) in Phase II clinical trials was first introduced in the early 2000s. The MCP-Mod method has significantly transformed the way dose-finding studies
发表于 2025-3-23 23:12:50 | 显示全部楼层
发表于 2025-3-24 05:11:54 | 显示全部楼层
发表于 2025-3-24 08:19:27 | 显示全部楼层
发表于 2025-3-24 12:20:49 | 显示全部楼层
Book 2025ook details advancements made in drug development...Finding the right dose(s) is one of the most important objectives in new drug development. In Phase I clinical development, one of the objectives is to escalate test doses from low to high. The low doses should be safe, then escalate up to the maxi
发表于 2025-3-24 17:20:53 | 显示全部楼层
Adam Smith. New Intuitions For A New Age,sents a curve-free design and a hybrid design for BED-finding trials involving one agent, assuming a monotonic dose–toxicity curve and a unimodal dose–efficacy curve. The last section of the chapter provides examples and demonstrations of our Web-based R packages.
发表于 2025-3-24 19:30:15 | 显示全部楼层
Monotonic Dose–Response and Curve-Free Designs for Phase I Dose-Finding Trialssents a curve-free design and a hybrid design for BED-finding trials involving one agent, assuming a monotonic dose–toxicity curve and a unimodal dose–efficacy curve. The last section of the chapter provides examples and demonstrations of our Web-based R packages.
发表于 2025-3-25 02:07:51 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-20 00:58
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表